{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T08:01:07Z","timestamp":1764403267506},"reference-count":0,"publisher":"Pakistan Medical Association","issue":"4","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pak Med Assoc"],"abstract":"<jats:p>Objective: To assess cardiovascular risk after sofosbuvir and daclatasvir antiviral combination therapy in chronic hepatitis C virus patients.Methods: The prospective cohort study was conducted at the Kafrelsheikh University Hospital, Egypt, from December 2019 to December 2021, and comprised adult patients of either gender with chronic hepatitis C virus and with minimum ejection fraction 40%. They were classified into groups according to their cardiovascular risk. Group 1 had individuals with no risk factors, Group 2 had patients with many risk factors, Group 3 had patients with only hypertension, Group 4 had those with diabetes alone, and Group 5 comprised smokers. All the patients were evaluated for the risk of major cardiovascular events at baseline and at the end of 12-week of antiviral combination therapy of sofosbuvir 400 mg once daily dose and daclatasvir 60 mg once daily dose. Data was analysed with SPSS version 23.Results: Of the 200 patients, there were 96(48%) males and 104(52%) females. The age ranged 34-81 years. There were 78(39%) patients in Group 1; 20(25.6%) males and 58(74.4%) females with mean age 54.4\u00b110.45 years. Group 2 had 60(30%) patients; 40(66.6%) males and 20(33.3%) females with mean age 59.57\u00b19.1 years. Group 3 had 25(12.5%) patients; 3(12%) males and 22(88%) females with mean age 61.4\u00b17.8 years. Group 4 had 13(6.5%) patients; 10(77%) males and 3(23%) females with mean age 55.4\u00b110.4 years. Group 5 had 24(12%) patients who were all (100%) males with mean age 60.7\u00b15.7 years. There were non-significant changes in the incidence of angina, arrhythmias or progression of dyspnoea (p&gt;0.05). Echocardiography follow-up results showed non-significant changes in meanejection fraction, global longitudinal strain and pulmonary artery pressure (p&gt;0.05).Conclusion: Sofosbuvir and daclatasvir combination therapy was found to be safe in chronic hepatitis C virus patients regarding cardiac risks.Keywords: Sofosbuvir, Daclatasvir, Stroke, Pulmonary, coronary syndrome, Cardiovascular, Hepatitis C, Ventricular dysfunction, Echocardiography, Amiodarone, Hypertension, Arrhythmias, Diabetes, Dyspnoea, Smoking.<\/jats:p>","DOI":"10.47391\/jpma.egy-s4-28","type":"journal-article","created":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T04:31:56Z","timestamp":1685853116000},"page":"S136-S141","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular Risk Assessment after Sofosbuvir and Daclatasvir Regimen for Chronic Hepatitis C Virus Infection"],"prefix":"10.47391","volume":"73","author":[{"family":"Kareem Ali Maher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Reda Biomy Bastawesy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mahmoud Mohammed AbdouYossef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mariam Salah Zaghlol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Wael Anwer Haseeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26547","published-online":{"date-parts":[[2023,5,25]]},"container-title":["Journal of the Pakistan Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/download\/9838\/2392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/download\/9838\/2392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T04:31:56Z","timestamp":1685853116000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.jpma.org.pk\/index.php\/public_html\/article\/view\/9838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5,25]]}},"URL":"https:\/\/doi.org\/10.47391\/jpma.egy-s4-28","relation":{},"ISSN":["0030-9982"],"issn-type":[{"value":"0030-9982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,25]]}}}